Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.75    -0.065 (-1.35%)
Bid:
4.72
Ask:
4.785
Spread: 0.065 (1.377%)
Market Cap: £227.98m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Master License Agreement

29 Jun 2007 10:11

Seeing Machines Limited29 June 2007 29 June 2007 Seeing Machines Limited ("Seeing Machines" or the "Company") SEEING MACHINES AND THE AUSTRALIAN NATIONAL UNIVERSITY SIGN MASTER DEVELOPMENT & COMMERCIALIZATION AGREEMENT Seeing Machines (AIM: SEE), a leading developer of advanced computer basedimaging software systems, announces today that it has concluded a masterdevelopment and commercialization agreement with the Australian NationalUniversity (ANU). Under the terms of the agreement Seeing Machines will provide material supportto the research efforts of the ANU through the loan of materials, software,equipment and know-how. In return Seeing Machines acquires the first rights tocommercialize all intellectual property generated by the research activitiesconducted within the ANU and supported by the materials. Dr Fiona Nelms, Director of the Office of Commercialisation at the ANUcommented: "This agreement furthers the strong relationship between ANU andSeeing Machines with an aim to develop state of the art diagnostic tools forglaucoma and other eye diseases. Our collaboration to date has enabled ANU IP todevelop in a commercial setting thereby increasing the chance of successfulproduct development, and we look forward to building on this with the executionof this new agreement." Nick Cerneaz CEO of Seeing Machines said: "This agreement cements the strongfoundation that has been established between the Company and the University overthe last few years. We have worked very closely with the world class team at theResearch School of Biological Sciences at ANU for the development of theTrueField Analyzer, and we are tremendously excited about the pipeline of futureapplications that can be built on that base platform. There are already a numberof research activities underway within the University that are supported bymaterials from Seeing Machines and come under the scope of this agreement, andwe look forward to realizing the potential of that work in the future." Further information about Seeing Machines can be obtained from the companywebsite www.seeingmachines.com. --- ENDS --- Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Peter Ward Clare Irvine+61 (0) 2 6125 6501 +44 (0) 20 7190 7015 +44 (0) 20 7851 7480www.seeingmachines.com Notes to editors: About Seeing Machines Seeing Machines is an award winning Technology Company which focuses on visionbased human machine interfaces. Formed in 2000 in Canberra, Australia, SeeingMachines' purpose is to commercialise its computer-vision across a range ofindustries and applications. Seeing Machines deliver advanced computer vision solutions for researches anddevelopers in human factors, transportation safety, computer human interaction,robotics, medical research and psychology. The flagship product faceLAB(R)provides an automated and contact-free gaze and head tracking technology, itsolves the problem of observing human behaviour naturally, non-intrusively andwith a high degree of accuracy and usability. Building on these unique facetracking and pupil measurement and monitoring capabilities, the TrueFieldAnalyzer(R) is a development undertaken by Seeing Machines in partnership withcolleagues from the Research School of Biological Sciences (RSBS) at theAustralian National University (ANU). The TrueField Analyzer(R) offers a new objective method to help doctors diagnoseand manage a range of eye diseases including glaucoma, age related maculardegeneration and diabetic retinopathy. Glaucoma affects about 2-3% of thepopulation over 40 years of age and is a leading source of blindness. Unlikemost other devices available to the clinician the TrueField Analyzer is acompletely objective test and it is quick and easy for patients and techniciansalike. The device measures both eyes concurrently and due to the reliabilitythat arises from the objective nature of the test, it has the potential tobecome a new standard in the measurement of visual field defects and thus in thediagnosis and management of disease such as glaucoma. More generally Seeing Machines' computer vision systems are able to measure theorientation and position of a human head, estimate eye-gaze direction, detecteye blinks and track other facial features. This functionality is achievedentirely though visual means, using video cameras connected to advanced imageprocessing software, with no attachments required on the subject. Products suchas faceLAB(R) are designed to allow human factors researchers and designers toassess the interaction of an operator in an environment and this findsapplication in designing operator environments, such as cockpits for cars,trucks, trains, and aeroplanes for instance, and other industrial designapplications, as well as medical and psychological research situations. Thetechnology also has application in monitoring automobile drivers and if itdetects drowsiness or that the driver is distracted and their attention has beendiverted from the road, an alarm can be raised to alert the driver to eitherpull over and rest in the case of drowsiness or to pay more attention to theroad. The systems work in real-time, enabling the behaviour of subjects to be trackedin real-time. This technology is paving the way in promoting safer drivingconditions and works to enhance the driving experience and to eliminateaccidents caused through driver drowsiness or distraction. There are many different sectors that can benefit from this revolutionarysoftware, for which it has been developed, including: automotive; academicresearch; medicine/healthcare; defence; autostereoscopy (next generationdisplays); sport; and games. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
9th May 20227:00 amRNSSeeing Machines collaboration in optics technology
21st Apr 20227:00 amRNSCollaboration with leading systems supplier
20th Apr 20227:00 amRNSSeeing Machines inks additional Occula NPU licence
30th Mar 20227:00 amRNSHalf-year results and financial report
28th Feb 202211:45 amRNSDirector/PDMR Shareholding
24th Feb 20227:00 amRNSSeeing Machines, Air Ambulance Victoria contract
23rd Feb 20227:00 amRNSHalf year trading update
16th Feb 20229:00 amRNSHolding(s) in Company
24th Jan 20227:00 amRNSIIHS Implementation of New Safety Ratings
6th Jan 202212:30 pmRNSSeeing Machines & Qualcomm to demo at CES 2022
6th Jan 202210:01 amRNSAmbarella & Seeing Machines Collaboration
5th Jan 202211:02 amRNSOmniVision & Seeing Machines ASIC Collaboration
31st Dec 20217:00 amRNSWithdrawal from in-person attendance at CES 2022
23rd Dec 202110:30 amRNSIssue of Performance Rights
16th Dec 20218:30 amRNSResult of AGM
16th Dec 20217:00 amRNSLargest Driver & Occupant Monitoring System Award
15th Dec 20218:08 amRNSFY 2021 Annual Report
14th Dec 202110:30 amRNSDirector/PDMR Shareholding
13th Dec 202110:00 amRNSDirector/PDMR Shareholding
9th Dec 20219:15 amRNSDirector/PDMR Shareholding
6th Dec 202110:00 amRNSNotice of AGM
1st Dec 202112:15 pmRNSHolding(s) in Company
1st Dec 202112:00 pmRNSDirector/PDMR Shareholding
1st Dec 20217:00 amRNSTotal Voting Rights
26th Nov 202110:00 amRNSDirector/PDMR Shareholding
26th Nov 20219:48 amRNSDirector/PDMR Shareholding
24th Nov 202110:52 amRNSIssue of Equity
24th Nov 20217:00 amRNSYear End Results
23rd Nov 20217:00 amRNSResult of Fundraise
22nd Nov 20214:37 pmRNSRetail Offer via PrimaryBid
22nd Nov 20214:35 pmRNSProposed Fundraise to Raise a Minimum of US$40m
15th Nov 20217:00 amRNSCollins Aerospace & Seeing Machines Collaboration
10th Nov 20217:00 amRNSChange of Nominated Adviser
8th Nov 20217:00 amRNSBipartisan infrastructure legislation
2nd Nov 20217:00 amRNSInvestor Presentation
18th Oct 20217:37 amRNSNotice of Results
13th Oct 20217:00 amRNSSeeing Machines establishes European sales team
11th Oct 20217:00 amRNSGlobal Framework Agreement with Shell
23rd Sep 20212:00 pmRNSSeeing Machines unveils its Occula® NPU
16th Aug 20217:13 amRNSLeading software provider integrates Guardian
11th Aug 20217:00 amRNSBipartisan Senate legislation
10th Aug 20217:00 amRNSHolding(s) in Company
3rd Aug 20217:00 amRNSFY21 trading update
14th Jul 20218:27 amRNSSeeing Machines moves to SETS trading platform
7th Jul 20217:00 amRNSAgreement with Airservices Australia
5th Jul 202111:58 amRNSIssue of Shares and Total Voting Rights
30th Jun 20217:00 amRNSDirector/PDMR Shareholding
28th Jun 20212:42 pmRNSDirector/PDMR Shareholding
23rd Jun 20212:05 pmRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSSEE DMS available across five new vehicle models

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.